Fig. 9

RECIST criteria applied to the therapeutic assay of liposomes. B16OVA tumor bearing mice intravenously administered with three cycles (cycle/every 72 h) of different treatments: saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously administered at 3 mg/kg and tumor progression was measured twice per week. The values, expressed as percentage, were calculated comparing the tumor size at a specific time point with its initial size at day 7 after cell inoculation